Through these combined effects, SGLT2 inhibitors represent a promising therapeutic approach for addressing the multifaceted aspects of endothelial dysfunction, potentially reducing the risk of cardiovascular complications. This evidence concerns the gene SLC5A2 and endothelial dysfunction.